Scabies
Methodology & AI Transparency ⓘ
Scabies Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Scabies is an itchy skin condition caused by the microscopic mite Sarcoptes scabei.
- 2 Real-world patient consensus: Clinical coding for Scabies uses ICD-10 B86 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Differential triage of Scabies (B86) utilizes topical retinoids/calcineurin/steroid sparing in Scabies (B86: regimens).
- 4 Top reported side effects / signs: Objective lab/clinical target for Scabies: Fasting Lipids & in Scabies (B86: ALT (if systemic) (Within baseline reference limits (B86)) and 25-Hydroxy Vitamin D in Scabies (B86: & hs-CRP).
Ask our AI Specialists anything about Scabies
What Is Scabies?
Scabies is an itchy skin condition caused by the microscopic mite Sarcoptes scabei. It is common all over the world, and can affect anyone. Scabies spreads quickly in crowded conditions where there is frequent skin-to-skin contact between people. Hospitals, child-care centers, and nursing homes are examples. Scabies can easily infect sex partners and other household members. Sharing clothes, towels, and bedding can sometimes spread scabies. This can happen much more easily when the infested person has crusted scabies. You cannot get scabies from a pet. Pets get a different mite infection called mange.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Scabies (ICD-10 B86) is driven by cutaneous immune skewing in Scabies (B86: (Th2/IL-4/IL-13 in atopic); Cross-referenced with NIH MeSH (Scabies), specialists in Dermatology: Acne, Eczema, Psoriasis & Rosacea monitor 25-Hydroxy Vitamin D in Scabies (B86: & hs-CRP) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Pimple-like irritations or a rash
- • Intense itching, especially at night
- • Presentation of Scabies (B86): recurrent flares triggered in Scabies (B86: by UV exposure,)
- • Secondary Scabies clinical sign: persistent erythematous plaques, in Scabies (B86: scaly patches, pruritic)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Scabies Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B86 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Scabies (B86: ALT (if systemic) | Within baseline reference limits (B86) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Scabies (B86: & hs-CRP) | 25(OH)D 40–65 ng/mL (B86) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Scabies (B86: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (B86) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Scabies
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Elimite (Permethrin) Elimite • RxCUI 106387-B59651834 | Pyrethroid | 79% | $0.2393 | $ 16.25 /mo |
| Permethrin Nix, Nix Complete Lice Treatment • RxCUI 106387 | Pyrethroid | 88% | $0.2245 | $ 16.25 /mo |
| Psorinum (Scabies Lesion Lysate (Human)) Psorinum • RxCUI RXN-B02207604 | FDA Prescription Therapeutic Agent | 91% | $2.5900 | $ 194.98 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Scabies)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the RelaBoNT-A (60 U) treatment provided statistically significant improvement of moderate-to-severe LCL. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] • 2025-03-01 • Phase III Randomized Trial | N = 73 | 88/100 | PMID 39692332 ↗ |
| Can This Approach Help? Inside the Latest Research on Early disease intervention with guselkumab in psoriasis leads to a higher rate of Guselkumab efficacy was consistent across subpopulations, on the skin and systemically. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37262309 ↗ |
| Can This Approach Help? Inside the Latest Research on Liposomal tretinoin for uncomplicated acne Liposomal encapsulation of tretinoin allows reduction of the concentration of the active agent without a decline in efficacy for acne vulgaris. The Clinical investigator • 1994-12-15 • Randomized Controlled Trial | N = 20 | 88/100 | PMID 7711421 ↗ |
| Can This Approach Help? Inside the Latest Research on Gold-standard blind multicenter study comparing acitretin-PUVA, etretinate-PUVA Acitretin-PUVA treatment was significantly superior to placebo-PUVA with respect to several items (decrease in lesional scores after 6 weeks of therapy, number of PUVA exposures, and total dose of UVA until full symptom relief). Dermatologica • 1988-01-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 2976000 ↗ |
| What the Latest Evidence Really Says About Effectiveness of Janus kinase inhibitors in treating JAK inhibitors appear to be effective in treating eczema. Dermatologic therapy • 2020-07-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 32463149 ↗ |
Scabies Patient Community & “People Like Me” Threads
Filter Scabies community threads and patient logs by age, biological sex, dosage, and treatment duration.